VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Immuno-Oncology 2022 | What role will TILs play in treating patients with melanoma?

Maartje Rohaan, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, comments on the clinical implications of the recent findings of a Phase III trial (NCT02278887) assessing tumor-infiltrating lymphocytes (TIL) in patients with metastatic melanoma. The study is one of the first to compare cell therapies in solid tumors against the standard of care such as ipilimumab. TILs have shows benefit in patients refractory to PD-1 inhibitors and more research is needed to assess this cell therapy against other immunotherapies. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter